Stock comparison
Genmab A/S
Phibro Animal Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
PAHC
Phibro Animal Health
Market cap
$1.35B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | PAHC | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 47D | GMAB |
| Benjamin Graham | 64C | 80A | PAHC |
| Philip Fisher | 48D | 31F | GMAB |
| Peter Lynch | 25F | 35D | PAHC |
| Joel Greenblatt | 76B | 44D | GMAB |
| Charlie Munger | 68C | 42D | GMAB |
| Terry Smith | 71C | 38D | GMAB |
Side-by-side metrics
| Metric | GMAB | PAHC |
|---|---|---|
| Market cap | $16.5B | $1.35B |
| P/E (TTM) | 6.2x | 15.5x |
| EV/EBIT | 12.0x | 20.0x |
| ROIC (TTM) | 43.78% | 11.17% |
| Gross margin | 93.88% | 32.54% |
| Net margin | 18.23% | 6.35% |
| Revenue CAGR 5y | -18.45% | 11.68% |
| EPS CAGR 5y | -23.48% | -2.92% |
| Debt / Equity | 0.1x | 2.2x |
| Dividend yield | 0.0% | 1.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 2.2x+97%
- Market cap$16.5Bvs $1.35B+92%
- ROIC (TTM)43.78%vs 11.17%+74%
- Gross margin93.88%vs 32.54%+65%
PAHC leads on
- Revenue CAGR 5y11.68%vs -18.45%+163%
- Dividend yield1.32%vs 0.0%+100%
- EPS CAGR 5y-2.92%vs -23.48%+88%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.